- The shares of CVS Health Corp (NYSE: CVS) received a price target increase from $95 to $101 from Deutsche Bank. These are the details.
The shares of CVS Health Corp (NYSE: CVS) received a price target increase from $95 to $101 from Deutsche Bank. And Deutsche Bank analyst George Hill is maintaining a “Buy” rating on the company shares following solid second-quarter results.
The second-quarter highlights include total revenues increasing to $72.6 million, up 11.1% compared to the prior year. The GAAP diluted EPS was $2.10 and Adjusted EPS was $2.42.
For the year-to-date, total revenues increased to $141.7 billion, up 7.3% compared to the prior year. And the GAAP diluted EPS was $3.78 and the Adjusted EPS was $4.46. The company generated cash flow from operations of $8.7 billion and they repaid $5.4 billion of long-term debt.
In terms of the full-year guidance, the company raised GAAP diluted EPS guidance range from $6.35 to $6.45 from $6.24 to $6.36. And they raised the Adjusted EPS guidance range from $7.70 to $7.80 from $7.56 to $7.68. Plus the raised cash flow from operations guidance range from $12.5 billion to $13 billion from $12 billion to $12.5 billion
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.